Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts give Rezolute a “Moderate Buy” consensus: Twelve of 14 analysts rate the stock a buy, with an average 12-month price target of $11.22.
• Recent analyst actions have been favorable, including HSBC’s upgrade to buy and Cantor Fitzgerald’s upgrade to overweight; several firms also raised their price targets.
• Rezolute reported a quarterly loss of $0.20 per share, missing the $0.15 consensus estimate. The stock opened at $4.38, while institutional investors own approximately 82.97% of shares.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $11.22.

A number of analysts recently weighed in on RZLT shares. HSBC raised shares of Rezolute to a "buy" rating in a research note on Friday, September 25th. HC Wainwright lifted their price objective on Rezolute from $5.00 to $10.00 and gave the company a "buy" rating in a report on Friday, September 25th. Citigroup reiterated an "outperform" rating on shares of Rezolute in a research note on Tuesday. Guggenheim increased their target price on Rezolute from $6.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, June 15th. Finally, Cantor Fitzgerald upgraded Rezolute from a "neutral" rating to an "overweight" rating in a research report on Monday.

Rezolute Price Performance

Shares of Rezolute stock opened at $4.38 on Thursday. The firm has a market capitalization of $423.63 million, a PE ratio of -5.76 and a beta of 0.53. The company's fifty day moving average price is $4.46 and its two-hundred day moving average price is $4.11. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). Analysts predict that Rezolute will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC acquired a new stake in shares of Rezolute in the 2nd quarter valued at $75,000. WINTON GROUP Ltd acquired a new stake in shares of Rezolute during the 2nd quarter worth about $88,000. Integrated Wealth Concepts LLC bought a new position in Rezolute during the 2nd quarter valued at about $143,000. Wellington Management Group LLP bought a new position in Rezolute during the 2nd quarter valued at about $276,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Rezolute in the second quarter valued at about $267,000. 82.97% of the stock is owned by institutional investors.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company's research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute's lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.